Plasma Androgen Receptor in Prostate Cancer
The therapeutic landscape of prostate cancer has expanded rapidly over the past 10 years, and there is now an even greater need to understand the biological mechanisms of resistance and to develop noninvasive biomarkers to guide treatment. The androgen receptor (AR) is known to be involved in the pa...
Main Authors: | Vincenza Conteduca, Giorgia Gurioli, Nicole Brighi, Cristian Lolli, Giuseppe Schepisi, Chiara Casadei, Salvatore Luca Burgio, Stefania Gargiulo, Giorgia Ravaglia, Lorena Rossi, Amelia Altavilla, Alberto Farolfi, Cecilia Menna, Sarah Pia Colangione, Mario Pulvirenti, Antonino Romeo, Ugo De Giorgi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/11/1719 |
Similar Items
-
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
by: Giorgia Gurioli, et al.
Published: (2020-09-01) -
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
by: Giuseppe Schepisi, et al.
Published: (2020-09-01) -
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
by: Giuseppe Schepisi, et al.
Published: (2021-02-01) -
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
by: Giuseppe Schepisi, et al.
Published: (2019-01-01) -
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
by: Vincenza Conteduca, et al.
Published: (2021-07-01)